Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for thiopurine-related hepatotoxicity in adults with inflammatory bowel disease
NL-OMON33536Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of acetylcysteine in Drug-induced hepatitis (DILI) and inflammatory bowel disease (IBD) (2 arms), sponsored by Vrije University Medical Center. Primary endpoint: Alteration of liver tests. Started Dec 2009; status: active, not recruiting.
02
Drugs
acetylcysteine
03
Conditions
Drug-induced hepatitis (DILI)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON33536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33536.